Published in Circulation on June 25, 2007
Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke (2011) 1.82
Factors associated with exacerbation of heart failure include treatment adherence and health literacy skills. Clin Pharmacol Ther (2009) 1.63
Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin (2009) 1.12
Novel biomarkers in chronic heart failure. Nat Rev Cardiol (2012) 1.06
Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol (2010) 0.88
Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart (2011) 0.86
Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy. J Vet Intern Med (2014) 0.81
Increased Rho kinase activity in congestive heart failure. Eur J Heart Fail (2012) 0.81
Elevated troponin T on discharge predicts poor outcome of decompensated heart failure. Heart Vessels (2010) 0.81
Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol (2012) 0.80
ICG-liver test versus new biomarkers as prognostic markers for prolonged length of stay in critically ill patients - a prospective study of accuracy for prediction of length of stay in the ICU. Ann Intensive Care (2014) 0.78
Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail (2014) 0.78
Cardiac Troponins in Dogs and Cats. J Vet Intern Med (2015) 0.78
Prognostic implication of physical signs of congestion in acute heart failure patients and its association with steady-state biomarker levels. PLoS One (2014) 0.77
Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev (2013) 0.76
Biomarkers in heart failure: the importance of inconvenient details. ESC Heart Fail (2015) 0.75
Development of autoimmune hair loss disease alopecia areata is associated with cardiac dysfunction in C3H/HeJ mice. PLoS One (2013) 0.75
Cationic isotachophoresis separation of the biomarker cardiac troponin I from a high-abundance contaminant, serum albumin. Electrophoresis (2014) 0.75
Letter by Ballo et al regarding article, "Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time". Circulation (2008) 0.75
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Universal definition of myocardial infarction. Circulation (2007) 11.69
Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol (2004) 8.97
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol (2011) 4.43
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol (2009) 4.16
Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA (2005) 3.89
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med (2002) 3.71
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med (2013) 3.65
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry (2005) 3.41
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res (2002) 3.27
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: user beware. Clin Chem (2012) 3.25
Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem (2009) 3.24
Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol (2004) 3.19
Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation (2010) 3.07
Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol (2003) 2.87
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension (2007) 2.77
Redefinition of myocardial infarction: prospective evaluation in the community. Circulation (2006) 2.76
Agreement between patient reports of cardiovascular disease and patient medical records. Mayo Clin Proc (2005) 2.71
Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation (2009) 2.70
Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol (2005) 2.69
Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol (2003) 2.62
Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction. Health Psychol (2007) 2.57
Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol (2009) 2.53
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation (2014) 2.50
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol (2013) 2.46
Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem (2005) 2.43
Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation (2007) 2.43
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol (2009) 2.34
Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics (2004) 2.31
Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta (2007) 2.31
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J (2013) 2.30
Perioperative myocardial infarction. Circulation (2009) 2.30
Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience. Acad Med (2011) 2.29
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol (2013) 2.28
Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail (2012) 2.26
Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ (2005) 2.23
Comprehensive standardized data definitions for acute coronary syndrome research in emergency departments in Australasia. Emerg Med Australas (2010) 2.19
Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc (2005) 2.17
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J (2002) 2.11
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med (2006) 2.09
Interpreting changes in troponin--clinical judgment is essential. Clin Chem (2012) 2.06
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol (2003) 2.03
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem (2006) 1.94
Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail (2008) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88
Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J (2011) 1.86
B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med (2006) 1.85
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem (2009) 1.82
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 1.82
Quality specifications for B-type natriuretic peptide assays. Clin Chem (2005) 1.81
Development of a clinical prediction rule for 30-day cardiac events in emergency department patients with chest pain and possible acute coronary syndrome. Ann Emerg Med (2011) 1.78
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
Heart failure after myocardial infarction: a review. Am J Med (2002) 1.76
Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med (2003) 1.75
Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation*. Crit Care Med (2014) 1.75
Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc (2002) 1.74
The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension (2010) 1.74
Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation (2007) 1.72